Sunday, June 18, 2017 2:14:20 PM
https://www.goodrx.com/suboxone-tablet?hide_online_pharmacies=true&show_pet_friendly_pharmacies=false
then rough calculation would = ~$750-$1000/6 months FOR GENERIC SUBOXONE..which would argue that probuphine's value will be maximised as part of a larger company's suite of offerings, given the current competitive price disparity
the Indivior anticompetitive lawsuits on their film have not yet been settled (hovering like a dark cloud over Indivior's head)... so everything is in flux for them, incl viability of their film, due to the ease with which it is being smuggled into prisons... so probuphine cost needs to be competitive w/generic suboxone w/premium paid for the superior advantage of the probuphine delivery system .. value for probuphine = significant benefit for 6 month ease of use (maximising PT compliance), non-diversion (no smuggling it to prisons or selling parts for illegal consumption, steady state release of the product (no spikes/valleys as with tablets that can precipitate cravings & relapse)
"No more funding “Advocates for Opioid Recovery” which is essentially a pension plan for Patrick Kennedy and Newt Gingrich, who have done zilch for probuphine. No more funding “Female Opioid Research and Clinical Experts” who are just another voice getting lost in all the confusion"...AMEN
Recent TTNP News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2024 09:10:20 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/21/2024 12:32:38 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/19/2024 08:23:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:22:56 PM
- Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd. • GlobeNewswire Inc. • 08/19/2024 08:11:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/15/2024 01:29:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2024 01:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:33:11 PM
- Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria • GlobeNewswire Inc. • 01/25/2024 09:29:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:59:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:13:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:20 PM
- Titan Pharmaceuticals Announces Reverse Stock Split and Ratio • GlobeNewswire Inc. • 12/28/2023 09:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:47:46 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM